Last $1.41 USD
Change Today +0.03 / 2.17%
Volume 245.1K
CYTX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

cytori therapeutics inc (CYTX) Snapshot

Open
$1.38
Previous Close
$1.38
Day High
$1.41
Day Low
$1.37
52 Week High
11/5/13 - $3.93
52 Week Low
08/22/14 - $1.26
Market Cap
112.2M
Average Volume 10 Days
486.1K
EPS TTM
$-0.56
Shares Outstanding
79.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CYTORI THERAPEUTICS INC (CYTX)

cytori therapeutics inc (CYTX) Related Bloomberg News

View More Bloomberg News

cytori therapeutics inc (CYTX) Related Businessweek News

View More BusinessWeek News

cytori therapeutics inc (CYTX) Details

Cytori Therapeutics, Inc., a cell therapy company, develops cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and other medical conditions. It primarily provides the Celution System, a tissue processing system that automates the process of digesting fat tissue, releasing the ADRCs. The company also offers the StemSource Cell Bank, a suite of products to allow hospitals or tissue banks to cryopreserve adipose-derived stem and regenerative cells; and StemSource 900/MB, a research laboratory equipment. Its products also include Celution 800 System that has CE Mark approval for certain soft tissue procedures, such as breast reconstruction, tissue ischemia, deficiency or injury of skin, fat, and muscle and fascia, as well as soft tissue wounds or fistulae associated with trauma, diabetes, ischemia, and radiation injury. In addition, Cytori Therapeutics, Inc. develops products in therapeutic areas, such as the treatment of thermal burns, and orthopedics and sports medicine indications, as well as specifically heart failure due to ischemic heart disease. The company markets its systems, instrumentations, and consumables directly, as well as through a network of distributors to hospitals, clinics, tissue banks, stem cell banking companies, and researchers performing investigator-initiated and funded studies worldwide. Cytori Therapeutics, Inc. was founded in 1996 and is headquartered in San Diego, California.

115 Employees
Last Reported Date: 03/14/14
Founded in 1996

cytori therapeutics inc (CYTX) Top Compensated Officers

Chief Executive Officer, President, Principal...
Total Annual Compensation: $406.6K
President of Asia Pacific
Total Annual Compensation: $454.4K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $333.3K
Consultant
Total Annual Compensation: $389.9K
Executive Vice President of Marketing & Sales
Total Annual Compensation: $329.5K
Compensation as of Fiscal Year 2013.

cytori therapeutics inc (CYTX) Key Developments

Cytori Therapeutics, Inc. Appoints Tiago Girao as Vice President of Finance and Chief Financial Officer, Effective September 2, 2014

Cytori Therapeutics, Inc. announced that Mr. Tiago Girao has been appointed Vice President of Finance and Chief Financial Officer (CFO), with an effective start date of September 2, 2014. Mr. Girao joins Cytori Therapeutics as Vice President of Finance and CFO from NuVasive, Inc.

Cytori Therapeutics, Inc. Announces Executive Changes

Cytori Therapeutics, Inc. announced that Mark Saad, the company's Chief Financial Officer (CFO), has accepted a new opportunity and will be officially leaving Cytori, effective from August 11, 2014. Cytori has recruited a highly qualified candidate who is extremely familiar with Cytori and is currently employed at a local medical company to be next CFO and VP Finance. The Board of Directors has appointed Dr. Marc Hedrick, Cytori's President and Chief Executive Officer, to serve as Principal Financial Officer until a new CFO is appointed. Mr. Saad will remain as a consultant for the company and will continue to support the management team during the transition period.

Cytori Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Cytori Therapeutics, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported net loss of $11,828,000 or $0.15 per basic and diluted common share on product revenues of $935,000 along with operating loss of $10,685,000 against net loss of $3,211,000 or $0.05 per basic and diluted common share on product revenues of $1,408,000 along with operating loss of $6,363,000 a year ago. For the six months, the company reported net loss of $22,228,000 or $0.05 per basic and diluted common share on product revenues of $1,965,000 along with operating loss of $20,232,000 against net loss of $10,877,000 or $0.16 per basic and diluted common share on product revenues of $2,800,000 along with operating loss of $13,100,000 a year ago. Net cash used in operating activities was $18,137,000 compared to $17,014,000 a year ago. Purchases of property and equipment were $467,000 compared to $432,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYTX:US $1.41 USD +0.03

CYTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aastrom Biosciences Inc $3.87 USD 0.00
Cardica Inc $1.12 USD -0.01
International Stem Cell Corp $0.10 USD -0.005
Uroplasty Inc $2.63 USD -0.01
Vision Sciences Inc/DE $0.93 USD +0.0177
View Industry Companies
 

Industry Analysis

CYTX

Industry Average

Valuation CYTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.2x
Price/Book 94.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYTORI THERAPEUTICS INC, please visit www.cytori.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.